KYV-101

Phase 2Cell therapy

KKyverna Therapeutics

KYV-101 is one of 215 biologic programs targeting Autoimmune Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

214

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Myasthenia GravisActive, not recruiting

Systemic SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

Lupus NephritisActive, not recruiting

Secondary Progressive Multiple SclerosisActive, not recruiting

DermatomyositisActive, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Myasthenia GravisPhase 2/Phase 3

Active, not recruiting

Systemic SclerosisPhase 1/Phase 2

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Lupus NephritisPhase 1/Phase 2

Active, not recruiting

Secondary Progressive Multiple SclerosisPhase 2

Active, not recruiting

DermatomyositisPhase 1

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

KYV-101

KKyverna Therapeutics

Phase 2

1 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Avonex

EMD Serono

Preclinical

22 6

Campath

GGenzyme, a Sanofi Company

Preclinical

12 7

Flomax

Sanofi

Preclinical

1 8

Pred Forte

Lunesta

1 10

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Autoimmune Disease

NCT06152172

Phase 1/2Active, not recruiting

Systemic Sclerosis

NCT06400303

Q2 2027

Phase 1Recruiting

Multiple Sclerosis

NCT06138132

Q3 2027

Phase 1/2Active, not recruiting

Lupus Nephritis

NCT05938725

Q3 2028

PreclinicalRecruiting

Myasthenia Gravis

NCT06193889

Clinical

Trials by Indication[1]

Lupus Nephritis2 trials

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Active, not recruiting·KKyverna Therapeutics·Phase 1/2·NCT05938725·6 enrolled

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Active, not recruiting·KKyverna Therapeutics·Phase 1/2·NCT06342960·2 enrolled

Secondary Progressive Multiple Sclerosis1 trial

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Active, not recruiting·KKyverna Therapeutics·Phase 2·NCT06384976·120 enrolled

Multiple Sclerosis1 trial

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Recruiting·SStanford University·Phase 1·NCT06138132·12 enrolled

Autoimmune Disease1 trial

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Active, not recruiting·DDavid Porter·Phase 1·NCT06152172·24 enrolled

Dermatomyositis1 trial

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

Recruiting·SStanford University·Phase 1·NCT06298019·21 enrolled

3 more indications

Systemic Sclerosis1 trial

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Active, not recruiting·KKyverna Therapeutics·Phase 1/2·NCT06400303·3 enrolled

Long-term Follow-up1 trial

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Recruiting·KKyverna Therapeutics··NCT07403188·70 enrolled

Myasthenia Gravis1 trial

KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis

Recruiting·KKyverna Therapeutics·Preclinical·NCT06193889·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for KYV-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KYV-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KYV-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyverna Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: KKyverna Therapeutics

KYV-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q3 2028

Trials by Indication[1]

Lupus Nephritis2 trials

Secondary Progressive Multiple Sclerosis1 trial

Multiple Sclerosis1 trial

Autoimmune Disease1 trial

Dermatomyositis1 trial

Systemic Sclerosis1 trial

Long-term Follow-up1 trial

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News